CEO Executive AssistantInvestor relations in the biotech sector is one of the most CEO-centric functions in any industry. Biotech investors are buying the story as much as the science, and the story must be told credibly by the leader who owns it. This reality makes investor relations delegation more complex in biotech than in most other sectors, but it does not make delegation unnecessary. The question is not whether to delegate investor relations work, but which parts of it, to whom, and how.
A biotech CEO who personally handles every investor inquiry, manages every conference logistics detail, writes every earnings script, and builds every investor presentation deck is spending executive time on work that specialized professionals can handle. The CEO’s irreplaceable value in investor relations is scientific credibility, organizational authority, and relationship quality with key institutional investors. Everything supporting those three roles is a candidate for delegation.
The Head of Investor Relations as the Primary IR Delegate
In a public biotech company or a clinical-stage private biotech with significant institutional investors, a dedicated Head of Investor Relations or VP of Investor Relations is the CEO’s primary IR delegate. This person’s role is to manage the full investor relations function, which includes far more operational work than the CEO recognizes.
The Head of IR manages: the investor calendar and conference scheduling, the earnings call logistics and script preparation, the investor database and CRM, outreach to new investors for non-deal roadshows, coordination of analyst days and investor events, preparation of investor presentations, management of the investor relations sections of the company website, monitoring of investor sentiment and analyst coverage, and coordination with legal and finance for regulatory disclosure requirements.
The CEO’s IR role, when properly delegated, is concentrated in the highest-leverage activities: leading investor meetings with key institutional investors, presenting at major healthcare and biotech conferences, conducting the quarterly earnings call, building relationships with the most important investors in the cap table, and crafting the core investment narrative that the Head of IR then helps communicate consistently.
This division concentrates CEO time where CEO presence genuinely moves the needle.
Delegating Investor Meeting Preparation
One of the most time-intensive IR functions is investor meeting preparation: building presentation materials, preparing Q&A briefs, coordinating meeting logistics, and following up on investor requests. These are all delegatable functions.
The Head of IR should prepare the investor presentation (with CEO input on the investment narrative), the Q&A brief tailored to specific investor concerns, the meeting logistics, and the follow-up tracking. The CEO reviews the presentation and Q&A brief before use (typically a 30-minute review), conducts the meeting, and provides the Head of IR with notes on any commitments made or follow-up required. The Head of IR handles all follow-up.
This structure reduces the CEO’s per-meeting preparation time from two to three hours to 30 to 45 minutes while ensuring the materials are professionally prepared and investor-relationship follow-through is consistent.
Delegating the Sell-Side Analyst Relationship
Sell-side analyst coverage is important for biotech companies because analysts influence institutional investor sentiment and provide accessible scientific and commercial analysis for a broad investor audience. The Head of IR is the primary daily contact for sell-side analysts; the CEO is not.
Define a clear protocol for analyst engagement: routine analyst inquiries go to the Head of IR. Scientific or clinical data interpretation questions can be escalated to the CMO or CSO with IR coordination. Relationship-building meetings with lead analysts at coverage-initiating firms or at inflection point moments may warrant CEO participation; these should be planned by the Head of IR and treated as strategic engagements rather than routine conversations.
The CEO who fields daily calls from analysts is spending executive time on a relationship management function that can largely be handled by the Head of IR with appropriate escalation protocols.
Managing the Conference Calendar
Biotech conference season is intense: JP Morgan Healthcare Conference, ASCO, ASH, BIO, EuropaBio, and dozens of smaller investor, therapeutic area, and partnering conferences all compete for CEO time. Without a delegation structure, the CEO ends up managing conference logistics personally while also carrying all the relationship and presentation work.
The Head of IR should own the full conference calendar: which conferences to attend, what form of presentation or participation makes sense at each, logistics, scheduling, and follow-up. The CEO’s involvement is to approve the overall conference strategy at the beginning of each year, attend the conferences where CEO presence is strategic, and conduct the investor and partner meetings the Head of IR has scheduled.
The Head of IR manages the logistics of each conference engagement in detail: the one-on-ones scheduled, the order of meetings, the materials needed, and the post-conference investor follow-up. The CEO shows up, engages substantively, and moves to the next commitment. This division of labor is efficient and protects the quality of the CEO’s investor interactions.
Delegating the Non-Deal Roadshow
Non-deal roadshows (NDRs), where a biotech company meets with institutional investors to update them on progress without a capital raise attached, are a regular part of investor relations for publicly traded and late-clinical-stage biotechs. They are also time-intensive for the CEO.
The Head of IR manages all NDR logistics: targeting and scheduling investors, preparing the meeting materials, coordinating the roadshow schedule, and following up with investors post-roadshow. The CEO conducts the investor meetings during the roadshow. On less strategic NDRs, the CFO and/or CMO may conduct some meetings without the CEO, particularly for investors where the financial or clinical update is the primary agenda rather than CEO relationship investment.
Define which investor accounts always require CEO participation in NDRs and which can be managed by the CFO or CMO for efficiency. Tier 1 investors (top 10 to 15 shareholders by position size and engagement quality) should always see the CEO on NDRs. Other investors may be managed at a lower level without significantly damaging the investor relationship.
For guidance on how investor relations delegation connects to overall pharma and biotech CEO delegation strategy, see pharma CEO delegation guide, which covers how CEOs can build effective delegation structures across all externally facing functions.
Crisis IR Delegation
Biotech companies face IR crises: clinical trial failures, safety signals, FDA holds, key employee departures, and unexpected cash runway concerns. In crisis situations, the temptation to centralize all IR management with the CEO is understandable but often counterproductive.
The CEO’s crisis IR role is: defining the message, approving public disclosures, conducting the key investor communications, and representing the organization’s credibility. The Head of IR, working with legal counsel and the CFO, manages the operational dimensions of crisis IR: coordinating the disclosure process, managing the press release or 8-K, scheduling investor calls, and coordinating media response.
The CEO who tries to personally manage both the strategic messaging and the operational execution of a crisis IR response will do neither well. Division of labor, even in crisis, produces better outcomes.
Delegating Investor Relation Compliance
Public company IR involves significant regulatory compliance obligations: Regulation FD, SEC disclosure requirements, quiet period management, blackout period administration, and proxy-related communications. These compliance functions should be owned by Legal and the Head of IR, not the CEO.
Establish clear protocols for who reviews investor communications before publication (Legal and IR, not CEO for routine communications), who manages quiet period compliance (Legal and IR), and when the CEO must be personally involved in a disclosure decision (always for material non-public information decisions, major clinical data disclosures, and strategic transaction announcements).
According to Harvard Business Review guidance on CEO investor relations, the most effective public company CEOs invest their limited IR time in the highest-leverage activities: major investor relationships, quarterly earnings leadership, and strategic narrative development. Delegating operational IR to a skilled Head of IR is what makes this concentration of CEO time possible.
See pharma drug pipeline for context on how clinical pipeline milestones, which are among the most investor-sensitive disclosures in biotech, can be managed through an appropriate delegation framework that serves both scientific integrity and investor relations.
Measuring IR Delegation Effectiveness
Evaluate your IR delegation effectiveness with these metrics: How much of the CEO’s weekly time is spent on IR activities versus strategic scientific, commercial, and organizational leadership? What is the quality of the investor meetings the CEO does attend, measured by investor feedback and follow-up action? Is the organization’s investor story being communicated consistently by the Head of IR in CEO-absent interactions?
If the CEO is spending more than 20 to 25 percent of their time on IR in a non-deal period, the delegation structure is not working. If investor feedback indicates that meetings with the CEO are qualitatively different from meetings without the CEO in terms of insight and credibility, the delegation is probably at the right level. If the investor story is inconsistent across CEO and non-CEO communications, the Head of IR needs better briefing and closer alignment with the CEO’s narrative.
Building effective IR delegation is an ongoing project, not a one-time organizational design decision. It requires regular calibration between the CEO and Head of IR, honest assessment of what is working, and willingness to evolve the structure as the company’s investor relations needs change with stage, size, and market conditions.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.